Your browser does not support SVG.
Board of Directors
January 22, 2020
Dermavant Appoints Chris Chapman as Chief Commerci ...
January 15, 2020
Dermavant Enters into Exclusive License Agreement ...
Dermavant Enters into Exclusive License Agreement with JT for Development and Commercialization of Tapinarof in Japan
Dermavant Announces First Patient Dosed in Phase 2a Clinical Trial of Topical Dual JAK/Syk Inhibitor Cerdulatinib for Vitiligo
Dermavant Sciences Announces First Patient Dosed in PSOARING, its Pivotal Phase 3 Clinical Program for Tapinarof for the Topical Treatment of Plaque Psoriasis
Dermavant Sciences Appoints Timothy S. Nelson and Kenneth E. Ludlum to Board of Directors
Dermavant Sciences Announces Appointment of Cyril Allouche as Chief Financial Officer and Provides Recent Corporate Update